Page 3 - David Bartel News Today

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) CEO Yvonne Greenstreet sold 7,615 shares of the stock in a transaction on Thursday, April 27th. The stock was sold at an average price of $194.59, for a total value of $1,481,802.85. Following the transaction, the chief executive officer now directly owns 30,332 shares in the company, valued […]

Sumitomo Mitsui Financial Group began coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) in a research report sent to investors on Wednesday, Marketbeat reports. The brokerage issued a neutral rating and a $220.00 price objective on the biopharmaceutical company’s stock. Several other brokerages have also recently issued reports on ALNY. Morgan Stanley raised […]

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) President Akshay Vaishnaw sold 2,392 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, April 27th. The shares were sold at an average price of $194.59, for a total transaction of $465,459.28. Following the transaction, the president now directly owns 17,890 shares in the company, […]

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) CFO Jeffrey V. Poulton sold 977 shares of the business’s stock in a transaction dated Thursday, April 27th. The shares were sold at an average price of $194.59, for a total value of $190,114.43. Following the completion of the transaction, the chief financial officer now owns 11,706 shares […]

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) CMO Pushkal Garg sold 1,839 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, April 27th. The shares were sold at an average price of $194.59, for a total value of $357,851.01. Following the transaction, the chief marketing officer now owns 6,800 shares in the company, valued […]

Handelsbanken Fonder AB grew its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 50.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 192,294 shares of the biopharmaceutical company’s stock after acquiring an additional 64,701 shares during the quarter. Handelsbanken Fonder AB’s […]

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) and Sernova (OTCMKTS:SEOVF – Get Rating) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability. Profitability This table compares Alnylam Pharmaceuticals and Sernova’s net margins, return […]

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) EVP Indrani Lall Franchini sold 3,500 shares of the business’s stock in a transaction on Thursday, April 6th. The stock was sold at an average price of $210.00, for a total value of $735,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which […]

China Universal Asset Management Co. Ltd. raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 1,110.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,604 shares of the biopharmaceutical company’s stock after purchasing an additional 12,480 shares […]

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) had its target price increased by Morgan Stanley from $205.00 to $210.00 in a research report released on Tuesday, Benzinga reports. The firm currently has an equal weight rating on the biopharmaceutical company’s stock. A number of other research analysts have also issued reports on the company. JPMorgan Chase […]